English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, April 12, 2021
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
Wednesday, March 31, 2021
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
Tuesday, March 30, 2021
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
エーザイ、抗がん剤レンバチニブについてペムブロリズマブとの併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る2つの適応追加申請が欧州医薬品庁により受理
Friday, March 26, 2021
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021
Tuesday, March 23, 2021
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan
エーザイとMSD、「レンビマ(R)」(レンバチニブ)について日本において「切除不能な胸腺癌」の効能効果の承認を取得
Monday, March 22, 2021
エーザイ、川島工園において新注射剤棟/研究棟新築工事に着工
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575